Chimeric Therapeutics Halts CHM-2101 Trial and Updates Strategy
Key points
- CHM-2101 trial halted due to dose-limiting toxicities
- Company shifts focus to in vivo delivery pathway for CDH17
- Major cost reductions implemented, saving approximately $4 million annually
Full summary
Chimeric Therapeutics Limited (ASX: CHM) has ceased enrollment in its Phase 1 trial of CHM-2101, an autologous CDH17 CAR-T cell therapy for gastrointestinal cancers, following dose-limiting toxicities. The trial's Safety Monitoring Committee determined that Dose Level 3 is unsafe, leading to the cessation of enrollment and dosing. Despite the setback, the study demonstrated anti-tumor activity, supporting CDH17 as a valid target. The company is now focusing on an in vivo delivery approach, which is expected to be faster and less costly. Chimeric has also implemented significant cost reductions, expected to save approximately $4 million annually. The company is in discussions with potential funders and creditors, and its financial report for FY26 is expected to include a material uncertainty regarding its ability to continue as a going concern.
Outlook
Chimeric Therapeutics plans to focus on in vivo delivery of CDH17 and is in discussions with potential funders. The company's financial outlook remains uncertain.
Summary generated by a large language model. Please interpret with care.